Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/150438 
Year of Publication: 
2014
Citation: 
[Journal:] Health Economics Review [ISSN:] 2191-1991 [Volume:] 4 [Issue:] 31 [Publisher:] Springer [Place:] Heidelberg [Year:] 2014 [Pages:] 1-14
Publisher: 
Springer, Heidelberg
Abstract: 
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz) requires direct comparisons of the new drug with appropriate comparators determined by the Federal Joint Committee (G-BA). In case no head-to-head studies are available for direct comparisons, the submission of indirect comparisons is permitted to assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG) states a clear preference for head-to-head trials and defines strict requirements for indirect comparisons to be considered in the benefit assessment. Similar requirements also exist in other countries with mandatory health technology assessments (HTA), like France, England and Scotland. Our evaluation shows that a comparison of the different HTA regarding indirect comparisons is difficult. Overall, external preconditions and methodological requirements are demanding and hardly to fulfill by pharmaceutical companies for implementation of indirect comparisons in early benefit assessment. The determination of the appropriate comparators, outcomes, patient subgroups and study choice are the main target within indirect comparisons for the future. To compare and assess submitted indirect comparisons it would be desirable that a transparent process was established, including the mandatory publication of HTA-reports within Europe and international guidelines, accepted by a large number of HTA-agencies.
Subjects: 
AMNOG
Early benefit assessment
HAS
Indirect comparison
IQWiG
NICE
JEL: 
I18
Persistent Identifier of the first edition: 
Creative Commons License: 
cc-by Logo
Document Type: 
Article

Files in This Item:
File
Size
431.18 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.